Cadila Pharmaceuticals Unveils Dlorfast-M for Allergy Relief

Cadila Pharmaceuticals, one of the leading research-based pharmaceutical companies in India, has now launched Dlorfast-M Tablets.

It is a new fixed-dose combination tablet that contains 5 mg of Desloratadine (a novel antihistamine) and 10 mg of Montelukast (a leukotriene receptor antagonist), for the treatment of allergic rhinitis and urticaria. Millions of Indians are affected every year by allergic rhinitis and urticaria, which can contribute to impaired quality of life.

As allergic disorders are known to be increasing as a result of rising pollution, lifestyle, and genetics, Cadila is introducing Dlorfast-M Tablets, a dual-action formulation for the management of allergic rhinitis and urticaria, which systematically targets the histamine and leukotriene pathways with simultaneous action, providing extended and effective symptom relief which is routine with monotherapy.

Also Read: Advanced Formulation Technologies Streamlining Global Pharma Innovation

Desloratadine is an effective H?-antihistamine that blocks pruritus, edema, and nasal irritation, while Montelukast as a leukotriene receptor antagonist blocks inflammation, edema, and bronchiole smooth muscle contraction, leading to less airway obstruction. Clinical studies demonstrate that the dual-action formulation is effective in improving symptoms of respiratory allergies, while providing better compliance with once daily formulation.

Commenting on the launch, Dr. Rajiv I. Modi, Chairman and Managing Director of Cadila Pharmaceuticals Limited, said: “With the launch of Dlorfast-M, Cadila Pharmaceuticals continues its mission to provide accessible, effective, and innovative therapies to patients. This dual-action formulation addresses both histamine and leukotriene pathways, offering superior symptom control and improving quality of life for people living with allergies.”

With Dlorfast-M Tablets, Cadila Pharmaceuticals is continuing to build its presence in the growing allergy management market in India, providing patients with an effective, long-acting, and safe option for the management of allergy symptoms.